Related Experiment Videos
A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.
1Department of Chemical Pathology, Guy's, St Thomas's, and University Lewisham Hospital, London, UK. martin.crook@gstt.sthames.nhs.uk
Journal of Clinical Pathology
|November 7, 2000
Summary
Fibrate drugs, like bezafibrate, can paradoxically lower cardioprotective high-density lipoprotein (HDL) cholesterol. This case report details such a decline and discusses potential mechanisms and implications.
Area of Science:
- Pharmacology
- Cardiology
- Nephrology
Background:
- Fibrate medications are commonly prescribed to manage dyslipidemia.
- A paradoxical decrease in high-density lipoprotein (HDL)-cholesterol has been anecdotally reported with fibrate use.
- The clinical significance and underlying mechanisms of this HDL decline remain unclear.
Observation:
- This report details a patient experiencing a significant decrease in serum HDL-cholesterol while on combined therapy with simvastatin and bezafibrate.
- The patient also presented with impaired renal function, suspected to be interstitial nephritis.
Findings:
- The combined use of simvastatin and bezafibrate was associated with a notable reduction in HDL-cholesterol levels.
- The observed decline in HDL-cholesterol in this patient aligns with previous limited reports on fibrate-induced HDL reduction.
Implications:
- The paradoxical reduction in HDL-cholesterol may counteract the cardioprotective benefits of fibrates.
- Further research is warranted to elucidate the mechanisms behind fibrate-induced HDL decline.
- Clinicians should be vigilant for this adverse effect, especially in patients on combination lipid-lowering therapy.